Genmab — Januar 2021
-
CHMP Issues Positive Opinion Recommending Ofatumumab in Relapsing Multiple Sclerosis
Company AnnouncementNovartis receives positive CHMP opinion for subcutaneous ofatumumab for adult patients with relapsing forms of multiple sclerosis
Opinion based on Phase 3 ASCLEPIOS I and II studies
-
smukt - så en måneds tid og vi er i mål
-
-
God morgen.
-
-
@Doublo: det eneste sikre her i livet er bedemanden og skattefar. Der er ingen 100% sikkerhed i aktiemarkedet, heller ikke bunden for Genmab-kursen. Synes dog fremtiden for Genmab ser fornuftig ud på længere sigt, men meget kan ske både for Genmab og aktiemarkedet generelt.
-
Sabari was confident enough in amivantamab’s data to take a swipe at mobocertinib, saying the Takeda program matched up poorly on safety given Thursday’s results.
“The data, to me, that’s been publicly available does not look as good as the data for amivantamab, and unfortunately with their TKI you see a lot of wild-type EGFR inhibition tox[icity] like diarrhea and rash, which you don’t see as commonly with amivantamab,” Sabari said.
-
Genmab: HexaBody
https://www.proinvestor.com/index.php?p=debat_1&postid=90339 -
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind